Study Reveals Impact of Dengue and Zika Infections on Future Dengue Fever Risk
Research Overview
A recent study conducted in Nicaragua has provided insights into how previous infections with dengue and Zika viruses can affect an individual’s future risk of developing various types of dengue fever. Researchers tracked a cohort of children over several years, examining the influence of past viral encounters on their susceptibility to different dengue strains.
Dengue and Zika Viruses
Dengue and Zika viruses, transmitted by mosquitoes, can lead to significant health issues. Dengue has four distinct serotypes (DENV1-4), while Zika comprises a single strain. Following an infection, the body produces antibodies aimed at combating the virus. Typically, these antibodies provide protection against future infections of the same or closely related viruses. However, findings indicate that antibodies developed from Zika infections could heighten susceptibility to dengue types 3 and 4.
Influence of Past Infections
The study highlights the impact of previous dengue infections and antibody levels on susceptibility to new dengue strains. While high antibody levels can offer protection against certain types, they may inadvertently worsen illness in others.
Increased Risks from Prior Exposure
The Pediatric Dengue Cohort Study monitored 4,000 participants aged two to 17 years in Managua, Nicaragua, since 2004. During the 2022-2023 epidemic, all four dengue virus serotypes were found to be circulating simultaneously. Individuals with past dengue or Zika infections exhibited a higher likelihood of symptomatic dengue infections. Specifically, those with a previous Zika infection were 1.61 times more likely to develop symptomatic dengue fever, especially with DENV3 and DENV4 serotypes. This increased risk remained significant over time, with a 1.87-fold increase in symptomatic dengue and a 3.62-fold rise in severe dengue noted years post-infection.
Risk Factors from Previous Dengue Infections
Prior dengue infections significantly raised the risk of symptomatic DENV2 and DENV4 infections, although no increased risk was observed for DENV1 or DENV3. Notably, a single previous dengue infection did not elevate the overall risk of symptomatic dengue, but it did increase the risk of severe dengue by 1.67 times.
Complex Immunity Dynamics
The study also found that the sequence of previous Zika infections is critical, as specific combinations raised the risk of symptomatic dengue more than others. Individuals with two prior dengue infections were 2.66 times more likely to fall ill again, particularly with the DENV3 strain. Those with a history of dengue followed by Zika faced a 1.47 times higher risk of future dengue illness, significantly with DENV2 (2.53 times higher) and DENV4 (4.05 times higher), and were 3.26 times more likely to experience severe dengue. Conversely, individuals with multiple dengue infections or a combination of dengue and Zika did not show an increased risk.
Antibody Levels: A Double-Edged Sword
Antibody levels against dengue were shown to vary over time, influenced by previous outbreaks and the virus type. Pre-existing antibody levels play a crucial role in determining dengue risk based on the infecting serotype. Low-to-intermediate antibody levels increased vulnerability to DENV2 and DENV4 infections, while high levels provided protection against DENV1 and DENV3.
Although antibodies produced after a viral infection typically offer protection against reinfection, complications arise with similar viruses. Cross-reactivity among dengue strains can sometimes lead to increased susceptibility to different serotypes, particularly when antibody levels are low or moderate. This phenomenon, known as antibody-dependent enhancement (ADE), elucidates why an initial dengue infection may heighten susceptibility to severe illness from other dengue strains later.
Implications for Vaccine Development
These findings pose significant considerations for the development and implementation of dengue and Zika vaccines. The potential for Zika vaccines to increase the risk of severe dengue in individuals without prior exposure, along with the observation that even multiple previous dengue infections may not guarantee complete protection, underscores the necessity for a cautious approach in vaccination strategies for both diseases.
Health officials must take pre-existing immunity and the potential for previous infections to exacerbate subsequent illnesses into account when designing future vaccine initiatives. This new understanding could pave the way for safer and more effective vaccines for both dengue and Zika, ultimately protecting vulnerable populations more effectively.